PT2844292T - Antagonistas de st2l e métodos de utilização - Google Patents
Antagonistas de st2l e métodos de utilizaçãoInfo
- Publication number
- PT2844292T PT2844292T PT137851580T PT13785158T PT2844292T PT 2844292 T PT2844292 T PT 2844292T PT 137851580 T PT137851580 T PT 137851580T PT 13785158 T PT13785158 T PT 13785158T PT 2844292 T PT2844292 T PT 2844292T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- st2l antagonists
- st2l
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640407P | 2012-04-30 | 2012-04-30 | |
| US201261640238P | 2012-04-30 | 2012-04-30 | |
| US13/798,204 US9090694B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists |
| US13/798,226 US9212227B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2844292T true PT2844292T (pt) | 2019-11-26 |
Family
ID=49477497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137851580T PT2844292T (pt) | 2012-04-30 | 2013-04-29 | Antagonistas de st2l e métodos de utilização |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9212227B2 (pt) |
| EP (2) | EP3597219A1 (pt) |
| JP (3) | JP6283354B2 (pt) |
| KR (2) | KR20150008152A (pt) |
| CN (2) | CN107098973A (pt) |
| AR (1) | AR090909A1 (pt) |
| AU (2) | AU2013256645B2 (pt) |
| BR (1) | BR112014027165A2 (pt) |
| CA (1) | CA2871948C (pt) |
| CL (1) | CL2014002955A1 (pt) |
| CO (1) | CO7240389A2 (pt) |
| CR (1) | CR20140488A (pt) |
| CY (1) | CY1122308T1 (pt) |
| DK (1) | DK2844292T3 (pt) |
| EA (2) | EA031047B1 (pt) |
| EC (1) | ECSP14025178A (pt) |
| ES (1) | ES2755094T3 (pt) |
| HK (1) | HK1208182A1 (pt) |
| HR (1) | HRP20191884T1 (pt) |
| HU (1) | HUE045864T2 (pt) |
| IL (2) | IL235401B (pt) |
| LT (1) | LT2844292T (pt) |
| MX (2) | MX358134B (pt) |
| MY (1) | MY166062A (pt) |
| NI (1) | NI201400125A (pt) |
| NZ (3) | NZ729913A (pt) |
| PE (1) | PE20150641A1 (pt) |
| PH (2) | PH12014502435A1 (pt) |
| PL (1) | PL2844292T3 (pt) |
| PT (1) | PT2844292T (pt) |
| RS (1) | RS59511B1 (pt) |
| SG (2) | SG10201608525SA (pt) |
| SI (1) | SI2844292T1 (pt) |
| TW (3) | TWI700299B (pt) |
| UA (1) | UA118336C2 (pt) |
| UY (1) | UY34774A (pt) |
| WO (1) | WO2013165894A2 (pt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| CA2904377C (en) | 2013-03-15 | 2021-07-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| EP3157634B1 (en) | 2014-06-23 | 2018-12-12 | Bionomics, Inc. | Antibodies that bind lgr4 |
| EA201791029A1 (ru) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | Антитела против интерлейкина-33 и их применение |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| EP3265107B1 (en) | 2015-03-02 | 2024-10-02 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
| EP3313887A2 (en) * | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoclonal anti-il-1racp antibodies |
| CN109475622A (zh) * | 2016-01-14 | 2019-03-15 | 安奈普泰斯生物有限公司 | 使用il-33抑制剂抑制过敏反应 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| US20190202907A1 (en) * | 2016-09-02 | 2019-07-04 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
| US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| JP6995127B2 (ja) | 2017-02-10 | 2022-02-04 | ジェネンテック， インコーポレイテッド | 抗トリプターゼ抗体、その組成物、及びその使用 |
| EP3610041A1 (en) | 2017-04-13 | 2020-02-19 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| MX2020006119A (es) | 2017-12-21 | 2020-08-24 | Hoffmann La Roche | Anticuerpos de union a hla-a2/wt1. |
| JP7418337B2 (ja) | 2018-02-09 | 2024-01-19 | ジェネンテック， インコーポレイテッド | マスト細胞媒介性炎症性疾患の治療法及び診断法 |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantification of IL-33 |
| JP2022513406A (ja) * | 2018-10-31 | 2022-02-07 | デリニア インコーポレイテッド | 多価制御性ｔ細胞調節因子 |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | 迈威(上海)生物科技有限公司 | 用于测定人il-33/st2通路抑制剂的生物学活性的方法 |
| IL292442A (en) | 2019-11-04 | 2022-06-01 | Medimmune Ltd | Anti-il-33 therapeutic agent for the treatment of kidney disorders |
| WO2021089563A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| US20230110203A1 (en) | 2020-03-13 | 2023-04-13 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| IL296256A (en) | 2020-03-13 | 2022-11-01 | Genentech Inc | Antibodies against interleukin-33 and uses thereof |
| EP4132972A1 (en) | 2020-04-06 | 2023-02-15 | MedImmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
| MX2022014243A (es) | 2020-05-12 | 2022-12-02 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Proteina de union al antigeno st2. |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| EP4430072A1 (en) | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| AU2023223413A1 (en) * | 2022-02-24 | 2024-10-10 | Sinomab Bioscience Limited | Bispecific binding proteins against alarmins and uses thereof |
| CN115838425B (zh) * | 2022-08-31 | 2024-06-18 | 首都医科大学 | 一种靶向血管紧张素ii 1型受体细胞外第二环的抗体及其应用 |
| WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| DE69738806D1 (de) | 1996-10-10 | 2008-08-14 | Invitrogen Corp | Tierzellkulturmedium mit pflanzlichen nährstoffen |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (fr) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
| PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
| ATE489395T1 (de) | 2000-12-12 | 2010-12-15 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6649055B1 (en) | 2002-05-07 | 2003-11-18 | The United States Of America As Represented By The United States Department Of Energy | Pump station for radioactive waste water |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| CA2554735A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2006055347A2 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| JP5474531B2 (ja) | 2006-03-24 | 2014-04-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 操作されたヘテロ二量体タンパク質ドメイン |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| TWI454480B (zh) | 2006-08-18 | 2014-10-01 | Novartis Ag | 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途 |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| JP2010527936A (ja) * | 2007-05-18 | 2010-08-19 | メディミューン，エルエルシー | 炎症性疾患におけるｉｌ−３３ |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| HUE028536T2 (en) | 2008-01-07 | 2016-12-28 | Amgen Inc | Method for producing antibody to FC heterodimer molecules using electrostatic control effects |
| CA2722466A1 (en) | 2008-04-29 | 2009-11-05 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| US8637454B2 (en) | 2009-01-06 | 2014-01-28 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| US8817596B2 (en) | 2009-01-09 | 2014-08-26 | Futurewei Technologies, Inc. | Protecting ingress and egress of a label switched path |
| US7879978B2 (en) * | 2009-03-31 | 2011-02-01 | Centocor Ortho Biotech, Inc. | Macaca fascicularis ST2L |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CN102711810B (zh) | 2009-11-30 | 2015-04-22 | 詹森生物科技公司 | 效应子功能已消除的抗体Fc区突变体 |
| US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| JP5887337B2 (ja) | 2010-03-30 | 2016-03-16 | ヤンセン バイオテツク，インコーポレーテツド | ヒト化ｉｌ−２５抗体 |
| BR112012025728B1 (pt) | 2010-04-09 | 2022-01-11 | Critical Care Diagnostics, Inc | Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| JP6126991B2 (ja) | 2010-09-27 | 2017-05-10 | ヤンセン バイオテツク，インコーポレーテツド | ヒトｉｉ型コラーゲンに結合する抗体 |
| RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
| CA2824500C (en) | 2011-02-23 | 2020-02-25 | Georg Fertig | Antibodies against human il33r and uses thereof |
| US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
-
2013
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active IP Right Cessation
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko active IP Right Grant
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en active Application Filing
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
-
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
-
2015
- 2015-09-11 HK HK15108911.2A patent/HK1208182A1/xx not_active IP Right Cessation
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
-
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-10-16 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254569B (en) | st2l antagonists and methods of use | |
| HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
| HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
| HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
| HK1203493A1 (en) | Substituted azabicycles and use thereof | |
| EP2928384A4 (en) | ANCHORS CAPTURED BY THE FABRIC AND METHOD OF USE | |
| GB201216649D0 (en) | Agents and methods | |
| EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
| HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
| GB201211775D0 (en) | An electrode and use thereof | |
| EP2909285A4 (en) | GELIFYING AGENTS AND METHODS OF USE | |
| PL2864417T3 (pl) | Polimer i sposób zastosowania | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- |